Biological Nanotherapeutics for Liver Disease

Hepatology. 2021 Nov;74(5):2863-2875. doi: 10.1002/hep.31847. Epub 2021 Aug 30.

Abstract

Extracellular vesicles (EVs) are a heterogeneous group of biological nano-sized vesicles that are released from cells and contribute to intercellular communication. Emerging knowledge about their biogenesis, composition, release, and uptake has resulted in broad interest in elucidating their potential roles in disease pathophysiology. The distinct biological properties of these biological nanoparticles emphasize several appealing advantages for potential therapeutic applications compared with the use of synthetic nanoparticles. When administered systemically, EVs are taken up and sequestered within the liver, further emphasizing opportunities for therapeutic use. Consequently, there is growing interest in their use for liver diseases. EVs can be used directly as therapeutics, and several studies have highlighted the intrinsic therapeutic properties of mesenchymal stem cell-derived EVs for chronic and acute liver diseases. Alternatively, EVs can be modified to facilitate their use for the delivery of therapeutic cargo. In this review, we discuss the cellular sources of EV, provide a concise overview of their potential use in diverse processes, and outline several promising applications for the use of EV-based therapeutics for liver diseases. The use of EV-based therapeutics provides a viable approach to target hepatic pathophysiology.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Extracellular Vesicles / chemistry
  • Extracellular Vesicles / transplantation*
  • Humans
  • Liver Diseases / therapy*
  • Nanoparticle Drug Delivery System / chemistry*
  • Nanoparticle Drug Delivery System / therapeutic use

Substances

  • Nanoparticle Drug Delivery System